Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.27 USD
+0.05 (2.25%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $2.29 +0.02 (0.88%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Regulus Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 10 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 10 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 31 | 28 | 28 | 24 | 24 |
Income After Depreciation & Amortization | -31 | -28 | -28 | -14 | -17 |
Non-Operating Income | 2 | 1 | 1 | 0 | 0 |
Interest Expense | 1 | 1 | 1 | 2 | 2 |
Pretax Income | -30 | -28 | -28 | -16 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -28 | -28 | -16 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -28 | -28 | -16 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -31 | -28 | -27 | -14 | -16 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -31 | -28 | -28 | -14 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.96 | 15.26 | 8.57 | 3.50 | 1.73 |
Diluted EPS Before Non-Recurring Items | -1.58 | -1.86 | -3.20 | -4.50 | -10.80 |
Diluted Net EPS (GAAP) | 1.58 | -1.86 | -3.20 | -4.50 | -10.80 |
Fiscal Year end for Regulus Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.30 | 8.13 | 7.32 | 7.37 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.30 | -8.13 | -7.32 | -7.37 |
Non-Operating Income | NA | 0.35 | 0.44 | 0.47 | 0.42 |
Interest Expense | NA | 0.11 | 0.14 | 0.17 | 0.19 |
Pretax Income | NA | -8.06 | -7.82 | -7.01 | -7.14 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.06 | -7.82 | -7.01 | -7.14 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.06 | -7.82 | -7.01 | -7.14 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 20.22 | 19.63 | 19.10 | 16.84 |
Diluted EPS Before Non-Recurring Items | NA | -0.40 | -0.40 | -0.37 | -0.42 |
Diluted Net EPS (GAAP) | NA | 2.77 | -0.40 | -0.37 | -0.42 |